Juul gets OK to sell updated vaping device with age-gating technology

•2mo ago

Juul gets OK to sell updated vaping device with age-gating technology

Tap title to read story

0:00 / 1:15

The U.S. Food and Drug Administration has authorized Juul Labs to market its JUUL2 e-cigarette system, including tobacco- and menthol-flavored pods, marking the company’s first new device authorization in more than a decade. The FDA issued marketing granted orders dated Aug. 27, while announcing the decision publicly Aug. 28. The authorized pods contain 18 milligrams of nicotine per milliliter, equivalent to about 1.5% to 1.6%. FDA said its review found complete smoking cessation at six weeks among 19.9% to 34.6% of tobacco-pod users and 28.4% to 49.3% of menthol-pod users in company-submitted studies. The agency said benefits for adult smokers outweighed youth-related risks for the menthol product, while stressing authorization is not an endorsement or safety approval. JUUL2 also offers optional app-based age verification. Juul plans additional applications for flavors and nicotine strengths. Juul faced a 2022 marketing denial order, rescinded in 2024, before receiving original-product authorization again in 2025.

Published 2026-08-28 23:51:45 UTC · Published by JQJO

Prepared by Sidra · AI assisted

More context

Timeline

On June 23, 2022, FDA denied Juul authorization for products.
On June 6, 2024, FDA rescinded denial orders, reopening applications.
On July 17, 2025, FDA authorized Juul devices and pods.
On July 2023, Juul submitted JUUL2 marketing application to FDA.
On December 2023, Juul submitted menthol JUUL2 application to FDA.
On August 27, 2026, FDA issued JUUL2 marketing granted orders.
On August 28, 2026, FDA publicly announced three JUUL2 authorizations.
On August 28, 2026, authorized JUUL2 pods contained 18mg/mL nicotine.
On August 29, 2026, no newer material development was located.
Future months: Juul may seek authorization for additional flavors, strengths.
Future months: FDA will monitor marketing, youth uptake, and compliance.
Future years: JUUL2 could intensify competition among authorized vaping products.

Why it matters

Immediate US impact: Adults gain another federally authorized vaping option nationally. Possible long-term US impact: Authorization may reshape competition among regulated nicotine products. Reader priority: Readers should prioritize FDA documents, independent evidence, and updated coverage. Most Affected: Adult smokers, Juul, FDA, retailers, youth-protection advocates nationwide.

Coverage notes

Left: Coverage emphasizes youth risks, addiction concerns, and regulatory safeguards. Center: Coverage emphasizes authorization, evidence, restrictions, and unresolved youth risks. Right: Coverage emphasizes adult choice, smoking alternatives, and regulatory relief.